摘要
目的研究XELOX方案一线治疗局部进展期、转移性的疗效及安全性。方法经组织学证实的局部进展期、转移性或复发胃癌胃腺癌患者41例,接受XELOX方案化疗(奥沙利铂130mg/m2,静脉滴注3h,第1天,卡培他滨1000mg/m2,口服,2次/d,第1～14天,每3周重复)。每2周期后进行疗效评价。中位治疗4个周期。结果41例接受XELOX方案一线治疗的患者中,4例不可评价,CR2例,PR15例,总有效率为41.5%,SD11例,PD9例。中位疾病进展时间为6.2个月,中位生存期达到11.8个月。XELOX方案治疗中导致3-4度毒性,其中神经毒性4例,手足综合征3例,血液学毒学4例。结论XELOX方案作为一线治疗晚期或复发胃癌疗效肯定,毒副反应轻,患者耐受性好。
Objective To evaluate the efficacy and toxicity of the combined therapy with oxaliplatin and capecitabine （XELOX） in patients with advanced or recurrent gastric cancer. Methods Forty-one patients with previously untreated advanced or recurrent gastric cancer received intravenous infusion of oxaliplatin at the dose of 130 mg/m2 on day 1 and oral administration of capecitabine at 1000 mg/m2 twice a day on days 1-14. The chemotherapy was repeated every 2 weeks for a median of 4 cycles. Results Two of 41 patients achieved a complete response, and 15 had partial responses, with an overall response rate of 41.5%. Stable disease was observed in 11 patients and progressive disease in 9. The median time to progression and overall survival was 6.2 months and 11.8 months. All the 41 patients were evaluated for toxicity according to NCI criteria, 4 showed grade 3-4 neural toxicity, 4 had hematological toxicity and 3 had hand-foot syndrome. Conclusion The XELOX regimen shows good efficacy with an acceptable toxicity profile in advanced or recurrent gastric cancer patient.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2010年第3期599-601,共3页
Journal of Southern Medical University
关键词
胃肿瘤
奥沙利铂
卡培他滨
药物疗法
stomach neoplasms
oxaliplatin
capecitabine
drug therapy
作者简介
闵娜（1978-），女，本科，主治医师，电话：020-61639581．E—mail：abc863228@163．com
通讯作者：何本夫。E-mail：hebenfu@sina．com
